Advanced Biomed Inc. (ADVB)
SEC filings, financial facts, source resources, and Goglides workspace context for Advanced Biomed Inc..
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
5Results4Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
Rubrik: data-resilience growth is real, but cash conversion has to carry the post-IPO case
Rubrik reported FY2026 revenue of $1.3 billion, FY2026 operating cash flow of $282.9 million, a FY2026 net loss of $348.8 million and $380.2 million of cash. The thesis depends on subscription durability, data security demand, operating leverage, cash conversi
OpenCrowdStrike (CRWD): the liquidity-trap claim has to survive the float math
CrowdStrike is a premium cybersecurity platform with strong ARR and cash-flow evidence, but the sharper risk is valuation-liquidity sensitivity around catalysts, not a proven hidden lock-up squeeze.
OpenAudioEye: accessibility SaaS with a debt line hiding inside the growth story
AudioEye sits in a useful corner of software: websites and mobile apps keep needing accessibility testing, monitoring and remediation. The appeal is $41.2 million of ARR, about 78% GAAP gross margin and positive operating cash flow. The catch is that AEYE is s
OpenAdvanced Biomed: The No-Revenue Biotech That Just Swerved Into AI
Advanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
Open